EVIDENCE LIBRARY
How One Synthetic Cannabinoid Produced Two Effects in a Cell Assay
A frog oocyte model separated receptor activation from potassium channel blockade for WIN55,212-2.
Calling a compound a cannabinoid receptor agonist describes one way it can act. An and colleagues tested WIN55,212-2 in frog oocytes engineered to express cannabinoid receptors and selected potassium channels. The setup allowed the researchers to compare the behavior of different components of the signaling pathway.
Concentration changed which effect appeared
At lower concentrations, WIN55,212-2 activated CB1 and CB2 in the assay. At higher concentrations, the researchers found a direct block of the GIRK1/2 potassium channel. A different potassium channel, IRK1, did not respond in the same way. Among the comparator compounds tested, THC and CBD did not show the significant GIRK1/2 block observed with WIN55,212-2.
The experiment identifies two possible molecular actions in an engineered system. Clinical interpretation would require evidence that the relevant concentrations reached the tissue in question and that the channel effect contributed to the observed symptoms.